<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01642966</url>
  </required_header>
  <id_info>
    <org_study_id>PATRASCARDIOLOGY-12</org_study_id>
    <nct_id>NCT01642966</nct_id>
  </id_info>
  <brief_title>Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention</brief_title>
  <official_title>Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, single-blind, investigator-initiated, crossover study.&#xD;
      Patients with Acute Coronary Syndrome (ACS) subjected to percutaneous coronary intervention&#xD;
      (PCI), are randomized after informed consent, in a 1:1 ratio to either ticagrelor 90mg x2 or&#xD;
      prasugrel 10mg x1 for 15 days. At Day 15± 2 days, coronary diastolic blood flow velocity in&#xD;
      left anterior descending artery (LAD) is evaluated at baseline (bCBFV) and under 2 min&#xD;
      adenosine infusions (maximal diastolic CBFV- maxCBFV) at gradually increasing doses of&#xD;
      50μg/kg/min, 80μg/kg/min, 110μg/kg/min and 140μg/kg/min with at least 5 min recovery&#xD;
      intervals between infusions. A crossover directly to the alternate treatment is performed&#xD;
      followed by the same evaluation at Day 30±2 days .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the curve (AUC) of the maxCBFV (maximal diastolic blood flow velocity in left anterior descending artery)at gradually increasing doses of adenosine</measure>
    <time_frame>15 days</time_frame>
    <description>The primary outcome will be assessed 15 days after the onset of each study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The ratio of maximal diastolic blood flow velocity in left anterior descending artery/baseline diastolic blood flow velocity in left anterior descending artery for 50μg/kg/min adenosine infusion at the end of treatment periods</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of maximal diastolic blood flow velocity in left anterior descending artery/baseline diastolic blood flow velocity in left anterior descending artery for 80μg/kg/min adenosine infusion at the end of treatment periods</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of maximal diastolic blood flow velocity in left anterior descending artery/baseline diastolic blood flow velocity in left anterior descending artery for 110μg/kg/min adenosine infusion at the end of treatment periods</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of maximal diastolic blood flow velocity in left anterior descending artery/baseline diastolic blood flow velocity in left anterior descending artery for 140μg/kg/min adenosine infusion at the end of treatment periods</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prasugrel 10mg/day for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 90mg twice a day for 15 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Prasugrel 10mg/day for 15 days</description>
    <arm_group_label>Prasugrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 90mg twice a day for 15 days</description>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-74 years&#xD;
&#xD;
          -  Patients with acute coronary syndrome undergoing PCI with stenting&#xD;
&#xD;
          -  Sinus rhythm&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to prasugrel or ticagrelor&#xD;
&#xD;
          -  Requirement for oral anticoagulant prior to the Day 30 visit&#xD;
&#xD;
          -  Any previous history of ischemic stroke, intracranial hemorrhage or disease (neoplasm,&#xD;
             arteriovenous malformation, aneurysm)&#xD;
&#xD;
          -  Any active bleeding or history of gastrointestinal bleeding, genitourinary bleeding or&#xD;
             other site abnormal bleeding within the previous 3 months, other bleeding diathesis,&#xD;
             or considered by investigator to be at high risk for bleeding&#xD;
&#xD;
          -  Concomitant oral or IV therapy with strong CY P3A inhibitors (ketoconazole,&#xD;
             itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir,&#xD;
             saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice N1 L/d), CYP3A&#xD;
             substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3A&#xD;
             inducers (rifampin /rifampicin, phenytoin, carbamazepine).&#xD;
&#xD;
          -  Increased risk of bradycardiac events.&#xD;
&#xD;
          -  Dialysis required.&#xD;
&#xD;
          -  Severe uncontrolled chronic obstructive pulmonary disease&#xD;
&#xD;
          -  Known severe hepatic impairment&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 45%, severe left ventricular hypertrophy,&#xD;
             diastolic dysfunction, severe valve disease&#xD;
&#xD;
          -  Prior myocardial infarction, percutaneous coronary intervention or coronary artery&#xD;
             bypass grafting&#xD;
&#xD;
          -  Weight &lt; 60 Kg&#xD;
&#xD;
          -  Alcohol or narcotics abuse&#xD;
&#xD;
          -  Major periprocedural complications: death, cardiogenic shock, stent thrombosis,&#xD;
             arrhythmias requiring cardioversion/defibrillation, temporary pacemaker insertion or&#xD;
             intravenous antiarrhythmic agents, respiratory failure requiring intubation,&#xD;
             retroperitoneal bleeding, major bleeding (need for blood transfusion or drop in&#xD;
             haemoglobin post-PCI by ≥ 5 gr/ dl or intracranial bleeding), unsuccessful PCI&#xD;
             (residual stenosis &gt; 30% or flow &lt; ΤΙΜΙ 3) or planned staged PCI in the next 5 days&#xD;
             after randomization&#xD;
&#xD;
          -  Any residual stenosis &gt; 40% in LAD&#xD;
&#xD;
          -  Small vessels or diffuse coronary atherosclerosis&#xD;
&#xD;
          -  Inability to detect coronary blood flow in LAD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardiology Department Patras University Hospital</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>July 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2012</study_first_posted>
  <last_update_submitted>January 21, 2013</last_update_submitted>
  <last_update_submitted_qc>January 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Patras</investigator_affiliation>
    <investigator_full_name>Dimitrios Alexopoulos</investigator_full_name>
    <investigator_title>Professor of Cardiology, Director of Cardiology Department</investigator_title>
  </responsible_party>
  <keyword>ticagrelor</keyword>
  <keyword>doppler echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

